APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatomycoses Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Dermatomycoses Drug Industry Growth and Trends Forecast to 2032

26 December 2025107 pages

Choose your research edition.

Industry ResearchDermatomycoses Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatomycoses Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Dermatomycoses Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatomycoses Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatomycoses Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Dermatomycoses Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dermatomycoses Drug include Vyome Biosciences Pvt Ltd, Viamet Pharmaceuticals Inc, TGV-Laboratories, Sol-Gel Technologies Ltd, Novan Inc, Helix BioMedix Inc, Dermala Inc, Daewoong Pharmaceutical Co Ltd and Blueberry Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Dermatomycoses Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Dermatomycoses Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Dermatomycoses Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Dermatomycoses Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Dermatomycoses Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Dermatomycoses Drug Market by Company

Vyome Biosciences Pvt Ltd

Viamet Pharmaceuticals Inc

TGV-Laboratories

Sol-Gel Technologies Ltd

Novan Inc

Helix BioMedix Inc

Dermala Inc

Daewoong Pharmaceutical Co Ltd

Blueberry Therapeutics Ltd

Biolab Farmaceutica Ltda

Anacor Pharmaceuticals Inc

Dermatomycoses Drug Segment by Type

BB-2603

Dapaconazole

Clotrimazole

Others

Dermatomycoses Drug Segment by Application

Hospital

Clinic

Others

Dermatomycoses Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomycoses Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatomycoses Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomycoses Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dermatomycoses Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Dermatomycoses Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of BB-2603 Table 2. Major Company of Dapaconazole Table 3. Major Company of Clotrimazole Table 4. Major Company of Others Table 5. Global Dermatomycoses Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 7. Global Dermatomycoses Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Dermatomycoses Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Dermatomycoses Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Dermatomycoses Drug Price by Type (2021-2026) & (US$/Unit) Table 11. Global Dermatomycoses Drug Sales by Type (2027-2032) & (W Units) Table 12. Global Dermatomycoses Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Dermatomycoses Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Dermatomycoses Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Dermatomycoses Drug Price by Type (2027-2032) & (US$/Unit) Table 16. North America Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 17. North America Dermatomycoses Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 19. Europe Dermatomycoses Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 21. Asia-Pacific Dermatomycoses Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 23. Latin America Dermatomycoses Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 25. Middle East and Africa Dermatomycoses Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Dermatomycoses Drug Industry Trends Table 27. Dermatomycoses Drug Industry Drivers Table 28. Dermatomycoses Drug Industry Opportunities and Challenges Table 29. Dermatomycoses Drug Industry Restraints Table 30. Global Dermatomycoses Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Dermatomycoses Drug Revenue Market Share by Company (2021-2026) Table 32. Global Dermatomycoses Drug Sales by Company (2021-2026) & (W Units) Table 33. Global Dermatomycoses Drug Sales Share by Company (2021-2026) Table 34. Global Dermatomycoses Drug Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Dermatomycoses Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Dermatomycoses Drug Major Company Production Sites and Headquarters Table 37. Global Dermatomycoses Drug Company, Product Type & Application Table 38. Global Dermatomycoses Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Dermatomycoses Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Dermatomycoses Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Dermatomycoses Drug Sales by Region (2021-2026) & (W Units) Table 43. Global Dermatomycoses Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Dermatomycoses Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Dermatomycoses Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Dermatomycoses Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Dermatomycoses Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Dermatomycoses Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Dermatomycoses Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Dermatomycoses Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 54. Global Dermatomycoses Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Dermatomycoses Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Dermatomycoses Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Dermatomycoses Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Dermatomycoses Drug Sales by Application (2027-2032) & (W Units) Table 59. Global Dermatomycoses Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Dermatomycoses Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Dermatomycoses Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Dermatomycoses Drug Price by Application (2027-2032) & (US$/Unit) Table 63. North America Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 64. North America Dermatomycoses Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 66. Europe Dermatomycoses Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 68. Asia-Pacific Dermatomycoses Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 70. Latin America Dermatomycoses Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 72. Middle East and Africa Dermatomycoses Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Vyome Biosciences Pvt Ltd Company Information Table 74. Vyome Biosciences Pvt Ltd Business Overview Table 75. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio Table 77. Vyome Biosciences Pvt Ltd Recent Development Table 78. Viamet Pharmaceuticals Inc Company Information Table 79. Viamet Pharmaceuticals Inc Business Overview Table 80. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 82. Viamet Pharmaceuticals Inc Recent Development Table 83. TGV-Laboratories Company Information Table 84. TGV-Laboratories Business Overview Table 85. TGV-Laboratories Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. TGV-Laboratories Dermatomycoses Drug Product Portfolio Table 87. TGV-Laboratories Recent Development Table 88. Sol-Gel Technologies Ltd Company Information Table 89. Sol-Gel Technologies Ltd Business Overview Table 90. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio Table 92. Sol-Gel Technologies Ltd Recent Development Table 93. Novan Inc Company Information Table 94. Novan Inc Business Overview Table 95. Novan Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Novan Inc Dermatomycoses Drug Product Portfolio Table 97. Novan Inc Recent Development Table 98. Helix BioMedix Inc Company Information Table 99. Helix BioMedix Inc Business Overview Table 100. Helix BioMedix Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Helix BioMedix Inc Dermatomycoses Drug Product Portfolio Table 102. Helix BioMedix Inc Recent Development Table 103. Dermala Inc Company Information Table 104. Dermala Inc Business Overview Table 105. Dermala Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Dermala Inc Dermatomycoses Drug Product Portfolio Table 107. Dermala Inc Recent Development Table 108. Daewoong Pharmaceutical Co Ltd Company Information Table 109. Daewoong Pharmaceutical Co Ltd Business Overview Table 110. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio Table 112. Daewoong Pharmaceutical Co Ltd Recent Development Table 113. Blueberry Therapeutics Ltd Company Information Table 114. Blueberry Therapeutics Ltd Business Overview Table 115. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio Table 117. Blueberry Therapeutics Ltd Recent Development Table 118. Biolab Farmaceutica Ltda Company Information Table 119. Biolab Farmaceutica Ltda Business Overview Table 120. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio Table 122. Biolab Farmaceutica Ltda Recent Development Table 123. Anacor Pharmaceuticals Inc Company Information Table 124. Anacor Pharmaceuticals Inc Business Overview Table 125. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 127. Anacor Pharmaceuticals Inc Recent Development Table 128. North America Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 129. North America Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 130. North America Dermatomycoses Drug Sales Market Share by Country (2021-2026) Table 131. North America Dermatomycoses Drug Sales Forecast by Country (2027-2032) & (W Units) Table 132. North America Dermatomycoses Drug Sales Market Share Forecast by Country (2027-2032) Table 133. North America Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. North America Dermatomycoses Drug Market Size by Country (2021-2026) & (US$ Million) Table 135. North America Dermatomycoses Drug Market Share by Country (2021-2026) Table 136. North America Dermatomycoses Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. North America Dermatomycoses Drug Market Share Forecast by Country (2027-2032) Table 138. Europe Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 139. Europe Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 140. Europe Dermatomycoses Drug Sales Market Share by Country (2021-2026) Table 141. Europe Dermatomycoses Drug Sales Forecast by Country (2027-2032) & (W Units) Table 142. Europe Dermatomycoses Drug Sales Market Share Forecast by Country (2027-2032) Table 143. Europe Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Dermatomycoses Drug Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Dermatomycoses Drug Market Share by Country (2021-2026) Table 146. Europe Dermatomycoses Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Dermatomycoses Drug Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 150. Asia-Pacific Dermatomycoses Drug Sales Market Share by Country (2021-2026) Table 151. Asia-Pacific Dermatomycoses Drug Sales Forecast by Country (2027-2032) & (W Units) Table 152. Asia-Pacific Dermatomycoses Drug Sales Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Dermatomycoses Drug Market Size by Country (2021-2026) & (US$ Million) Table 155. Asia-Pacific Dermatomycoses Drug Market Share by Country (2021-2026) Table 156. Asia-Pacific Dermatomycoses Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Asia-Pacific Dermatomycoses Drug Market Share Forecast by Country (2027-2032) Table 158. Latin America Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 159. Latin America Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 160. Latin America Dermatomycoses Drug Sales Market Share by Country (2021-2026) Table 161. Latin America Dermatomycoses Drug Sales Forecast by Country (2027-2032) & (W Units) Table 162. Latin America Dermatomycoses Drug Sales Market Share Forecast by Country (2027-2032) Table 163. Latin America Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Dermatomycoses Drug Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Dermatomycoses Drug Market Share by Country (2021-2026) Table 166. Latin America Dermatomycoses Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Dermatomycoses Drug Market Share Forecast by Country (2027-2032) Table 168. Middle East and Africa Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 169. Middle East and Africa Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 170. Middle East and Africa Dermatomycoses Drug Sales Market Share by Country (2021-2026) Table 171. Middle East and Africa Dermatomycoses Drug Sales Forecast by Country (2027-2032) & (W Units) Table 172. Middle East and Africa Dermatomycoses Drug Sales Market Share Forecast by Country (2027-2032) Table 173. Middle East and Africa Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Middle East and Africa Dermatomycoses Drug Market Size by Country (2021-2026) & (US$ Million) Table 175. Middle East and Africa Dermatomycoses Drug Market Share by Country (2021-2026) Table 176. Middle East and Africa Dermatomycoses Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Middle East and Africa Dermatomycoses Drug Market Share Forecast by Country (2027-2032) Table 178. Key Raw Materials Table 179. Raw Materials Key Suppliers Table 180. Dermatomycoses Drug Distributors List Table 181. Dermatomycoses Drug Customers List Table 182. Research Programs/Design for This Report Table 183. Authors List of This Report Table 184. Secondary Sources Table 185. Primary Sources List of Figures Figure 1. Dermatomycoses Drug Image Figure 2. Global Dermatomycoses Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatomycoses Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatomycoses Drug Sales (2021-2032) & (W Units) Figure 5. BB-2603 Image Figure 6. Global BB-2603 Sales YoY Growth (2021-2032) & (W Units) Figure 7. Dapaconazole Image Figure 8. Global Dapaconazole Sales YoY Growth (2021-2032) & (W Units) Figure 9. Clotrimazole Image Figure 10. Global Clotrimazole Sales YoY Growth (2021-2032) & (W Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 13. Global Dermatomycoses Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Dermatomycoses Drug Market Share by Type 2025 VS 2032 Figure 15. North America Dermatomycoses Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Dermatomycoses Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Dermatomycoses Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Dermatomycoses Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Dermatomycoses Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Dermatomycoses Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Dermatomycoses Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Dermatomycoses Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Dermatomycoses Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Dermatomycoses Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Dermatomycoses Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 33. Global Dermatomycoses Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Dermatomycoses Drug Market Share by Application 2025 VS 2032 Figure 35. North America Dermatomycoses Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Dermatomycoses Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Dermatomycoses Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Dermatomycoses Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Dermatomycoses Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Dermatomycoses Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Dermatomycoses Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Dermatomycoses Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Dermatomycoses Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Dermatomycoses Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 46. North America Dermatomycoses Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Dermatomycoses Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. Europe Dermatomycoses Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Dermatomycoses Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Asia-Pacific Dermatomycoses Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Dermatomycoses Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Latin America Dermatomycoses Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Dermatomycoses Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Middle East and Africa Dermatomycoses Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Dermatomycoses Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Dermatomycoses Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Dermatomycoses Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Dermatomycoses Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • BB-2603
  • Dapaconazole
  • Clotrimazole
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Vyome Biosciences Pvt Ltd
  • Viamet Pharmaceuticals Inc
  • TGV-Laboratories
  • Sol-Gel Technologies Ltd
  • Novan Inc
  • Helix BioMedix Inc
  • Dermala Inc
  • Daewoong Pharmaceutical Co Ltd
  • Blueberry Therapeutics Ltd
  • Biolab Farmaceutica Ltda
  • Anacor Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dermatomycoses Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Dermatomycoses Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Dermatomycoses Drug Market by Type
  6. 1.3.1 BB-2603
  7. 1.3.2 Dapaconazole
  8. 1.3.3 Clotrimazole
  9. 1.3.4 Others
  10. 1.4 Global Dermatomycoses Drug Market Size by Type
  11. 1.4.1 Global Dermatomycoses Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Dermatomycoses Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Dermatomycoses Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Dermatomycoses Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Dermatomycoses Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Dermatomycoses Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Dermatomycoses Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Dermatomycoses Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Dermatomycoses Drug Industry Trends
  2. 2.2 Dermatomycoses Drug Industry Drivers
  3. 2.3 Dermatomycoses Drug Industry Opportunities and Challenges
  4. 2.4 Dermatomycoses Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Dermatomycoses Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Dermatomycoses Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Dermatomycoses Drug Price (2021-2026)
  4. 3.4 Global Dermatomycoses Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dermatomycoses Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Dermatomycoses Drug Company, Product Type & Application
  7. 3.7 Global Dermatomycoses Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dermatomycoses Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dermatomycoses Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dermatomycoses Drug Tier 1, Tier 2, and Tier 3
4 Dermatomycoses Drug Regional Status and Outlook
  1. 4.1 Global Dermatomycoses Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Dermatomycoses Drug Historic Market Size by Region
  3. 4.2.1 Global Dermatomycoses Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Dermatomycoses Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Dermatomycoses Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Dermatomycoses Drug Forecasted Market Size by Region
  7. 4.3.1 Global Dermatomycoses Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Dermatomycoses Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Dermatomycoses Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Dermatomycoses Drug by Application
  1. 5.1 Dermatomycoses Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatomycoses Drug Market Size by Application
  6. 5.2.1 Global Dermatomycoses Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Dermatomycoses Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Dermatomycoses Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Dermatomycoses Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Dermatomycoses Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Dermatomycoses Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Dermatomycoses Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Dermatomycoses Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Vyome Biosciences Pvt Ltd
  2. 6.1.1 Vyome Biosciences Pvt Ltd Company Information
  3. 6.1.2 Vyome Biosciences Pvt Ltd Business Overview
  4. 6.1.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio
  6. 6.1.5 Vyome Biosciences Pvt Ltd Recent Developments
  7. 6.2 Viamet Pharmaceuticals Inc
  8. 6.2.1 Viamet Pharmaceuticals Inc Company Information
  9. 6.2.2 Viamet Pharmaceuticals Inc Business Overview
  10. 6.2.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  12. 6.2.5 Viamet Pharmaceuticals Inc Recent Developments
  13. 6.3 TGV-Laboratories
  14. 6.3.1 TGV-Laboratories Company Information
  15. 6.3.2 TGV-Laboratories Business Overview
  16. 6.3.3 TGV-Laboratories Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 TGV-Laboratories Dermatomycoses Drug Product Portfolio
  18. 6.3.5 TGV-Laboratories Recent Developments
  19. 6.4 Sol-Gel Technologies Ltd
  20. 6.4.1 Sol-Gel Technologies Ltd Company Information
  21. 6.4.2 Sol-Gel Technologies Ltd Business Overview
  22. 6.4.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio
  24. 6.4.5 Sol-Gel Technologies Ltd Recent Developments
  25. 6.5 Novan Inc
  26. 6.5.1 Novan Inc Company Information
  27. 6.5.2 Novan Inc Business Overview
  28. 6.5.3 Novan Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novan Inc Dermatomycoses Drug Product Portfolio
  30. 6.5.5 Novan Inc Recent Developments
  31. 6.6 Helix BioMedix Inc
  32. 6.6.1 Helix BioMedix Inc Company Information
  33. 6.6.2 Helix BioMedix Inc Business Overview
  34. 6.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Portfolio
  36. 6.6.5 Helix BioMedix Inc Recent Developments
  37. 6.7 Dermala Inc
  38. 6.7.1 Dermala Inc Company Information
  39. 6.7.2 Dermala Inc Business Overview
  40. 6.7.3 Dermala Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Dermala Inc Dermatomycoses Drug Product Portfolio
  42. 6.7.5 Dermala Inc Recent Developments
  43. 6.8 Daewoong Pharmaceutical Co Ltd
  44. 6.8.1 Daewoong Pharmaceutical Co Ltd Company Information
  45. 6.8.2 Daewoong Pharmaceutical Co Ltd Business Overview
  46. 6.8.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio
  48. 6.8.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  49. 6.9 Blueberry Therapeutics Ltd
  50. 6.9.1 Blueberry Therapeutics Ltd Company Information
  51. 6.9.2 Blueberry Therapeutics Ltd Business Overview
  52. 6.9.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio
  54. 6.9.5 Blueberry Therapeutics Ltd Recent Developments
  55. 6.10 Biolab Farmaceutica Ltda
  56. 6.10.1 Biolab Farmaceutica Ltda Company Information
  57. 6.10.2 Biolab Farmaceutica Ltda Business Overview
  58. 6.10.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio
  60. 6.10.5 Biolab Farmaceutica Ltda Recent Developments
  61. 6.11 Anacor Pharmaceuticals Inc
  62. 6.11.1 Anacor Pharmaceuticals Inc Company Information
  63. 6.11.2 Anacor Pharmaceuticals Inc Business Overview
  64. 6.11.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  66. 6.11.5 Anacor Pharmaceuticals Inc Recent Developments
7 North America by Country
  1. 7.1 North America Dermatomycoses Drug Sales by Country
  2. 7.1.1 North America Dermatomycoses Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Dermatomycoses Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Dermatomycoses Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Dermatomycoses Drug Market Size by Country
  6. 7.2.1 North America Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Dermatomycoses Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Dermatomycoses Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Dermatomycoses Drug Sales by Country
  2. 8.1.1 Europe Dermatomycoses Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Dermatomycoses Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Dermatomycoses Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Dermatomycoses Drug Market Size by Country
  6. 8.2.1 Europe Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Dermatomycoses Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Dermatomycoses Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Dermatomycoses Drug Sales by Country
  2. 9.1.1 Asia-Pacific Dermatomycoses Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Dermatomycoses Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Dermatomycoses Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Dermatomycoses Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Dermatomycoses Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Dermatomycoses Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Dermatomycoses Drug Sales by Country
  2. 10.1.1 South America Dermatomycoses Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Dermatomycoses Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Dermatomycoses Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Dermatomycoses Drug Market Size by Country
  6. 10.2.1 South America Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Dermatomycoses Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Dermatomycoses Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Dermatomycoses Drug Sales by Country
  2. 11.1.1 Middle East and Africa Dermatomycoses Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Dermatomycoses Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Dermatomycoses Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Dermatomycoses Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Dermatomycoses Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Dermatomycoses Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Dermatomycoses Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Dermatomycoses Drug Value Chain Analysis
  2. 12.1.1 Dermatomycoses Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Dermatomycoses Drug Production Mode & Process
  7. 12.2 Dermatomycoses Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Dermatomycoses Drug Distributors
  10. 12.2.3 Dermatomycoses Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst